Clinical Commissioning Policy: Infliximab for Refractory or Progressive Neurosarcoidosis (Adults and Post-pubescent Children)

Infliximab will be available as a treatment option through routine commissioning for refractory or progressive neurosarcoidosis within the criteria set out in this document. The policy is restricted to certain age groups as there is insufficient evidence to confirm safety.


NHS England